Jang Albert, Rauterkus Grant P, Vaishampayan Ulka N, Barata Pedro C
Section of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA.
Tulane University School of Medicine, New Orleans, LA, USA.
Onco Targets Ther. 2022 Aug 26;15:897-912. doi: 10.2147/OTT.S285758. eCollection 2022.
Prostate cancer is one of the most common malignancies in men. Over time, it can metastasize and become lethal once it exhausts hormonal therapies and transitions into castration-resistant prostate cancer (CRPC). Several therapies have been recently approved for advanced prostate cancer, but identifying biomarkers for current treatments and searching for more effective treatments are urgently needed. Liquid biopsy is a powerful tool for isolating genetic material, proteins, and whole tumor cells from the blood. In recent decades, this technology has rapidly advanced, allowing for better insights into the pathogenesis and treatment response in different stages of prostate cancer. In this review, we summarize important clinical studies involving liquid biopsies in prostate cancer with a focus on advanced disease, notably regarding circulating tumor DNA, circulating tumor cells, and exosomes. We highlight the progress and the challenges that still exist for these technologies. Finally, we discuss promising avenues that will further expand the importance of liquid biopsy in the care for prostate cancer patients.
前列腺癌是男性最常见的恶性肿瘤之一。随着时间的推移，一旦它耗尽激素疗法并转变为去势抵抗性前列腺癌（CRPC），就会发生转移并变得致命。最近有几种疗法已被批准用于晚期前列腺癌，但迫切需要确定当前治疗的生物标志物并寻找更有效的治疗方法。液体活检是一种从血液中分离遗传物质、蛋白质和完整肿瘤细胞的强大工具。近几十年来，这项技术迅速发展，有助于更好地了解前列腺癌不同阶段的发病机制和治疗反应。在这篇综述中，我们总结了涉及前列腺癌液体活检的重要临床研究，重点是晚期疾病，特别是关于循环肿瘤DNA、循环肿瘤细胞和外泌体。我们强调了这些技术取得的进展以及仍然存在的挑战。最后，我们讨论了有前景的途径，这些途径将进一步扩大液体活检在前列腺癌患者护理中的重要性。
